Smartlab Europe

Press Releases

Novozymes Biopharma’s rAlbumin approved in Japan as MAQUET expands into new market

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that one of its leading customers has achieved approval of a medical device in Japan using Recombumin® Alpha - formerly Albucult®, a recombinant human albumin...

Promethera Biosciences opens the French part of its clinical trial in cell therapy

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today that it has successfully treated a patient with liver progenitor...

Trophos announces positive interim review in pivotal study of olesoxime in Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announces today the completion of the interim analysis of the pivotal efficacy study of olesoxime...

Okairos Initiates Phase I Clinical Trial Evaluating Vaccine against RSV Infections

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children. This clinical trial will enroll 40 healthy adult volunteers...

Quinten identifies a combination of two synergistic markers that predicts a favorable response to treatment in triple-negative breast cancer

Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the identification of two discriminating biological marker candidates which are indicative of a favorable response...

Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection

Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) today have decided to voluntarily recall all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which...

Shimojani Licenses New Stroke Therapy from Niigata University

  Shimojani LLC, a privately held biotech company, today announced that it has acquired an exclusive license from Niigata University for worldwide development and commercialization rights to an invention that has the potential to substantially reduce the risk of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »